JuanPabloFriasMD

Endocrinology • Los Angeles, CA

Diabetes, Lipid Metabolism, Obesity

Medical Director and Principal Investigator, National Research Institute

Join to view full profile

Dr. Frias is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Frias' full profile

Already have an account?

Office
2010 Wilshire Blvd.
Suite 303
Los Angeles, CA 90057
Phone+1 213-413-2500

Summary

Dr. Juan Frias is an endocrinologist in Los Angeles, CA and is affiliated with VA San Diego Healthcare System. He received his medical degree from Vanderbilt University School of Medicine and has been in practice 28 years. He specializes in diabetes and lipid metabolism.

Education & Training

University of California (San Diego) Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1997 - 1999
University of TennesseeResidency, Internal Medicine, 1995 - 1997
Vanderbilt University Medical CenterResidency, Internal Medicine, 1994 - 1995
US Naval HospitalInternship, Internal Medicine, 1989 - 1990
Vanderbilt University School of MedicineClass of 1989

Certifications & Licensure

CA State Medical License 1997 - 2025
FL State Medical License 1991 - 2014
CO State Medical License 2001 - 2003
TN State Medical License 1995 - 1997

Awards, Honors, & Recognition

Fellow (FACE) American Association of Clinical Endocrinology

Clinical Trials

Glycemic Response to Road Cycling in Type 1 Diabetes Start of enrollment: 2011 May 01
Unknown status
A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes Start of enrollment: 2014 Apr 15
Completed
Phase 2
A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2014 Apr 01
Terminated
Phase 2
Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients Start of enrollment: 2015 Aug 01
Completed
Not Applicable
An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2015 Oct 20
Completed
Phase 3
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia Start of enrollment: 2016 Dec 01
Completed
Phase 2
Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Start of enrollment: 2016 Nov 01
Completed
Phase 2
A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy Start of enrollment: 2016 Dec 01
Completed
Phase 2
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2017 May 24
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

8 citations
Cardiovascular efficacy and safety of antidiabetic agents: A network meta-analysis of randomized controlled trials.
Minji Sohn, Juan P Frias, Soo Lim
Diabetes, Obesity & Metabolism. 2023-12-01
15 citations
Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, plac...
Aditi R Saxena, Juan P Frias, Donal N Gorman, Rene N Lopez, Nabil Andrawis
Diabetes, Obesity & Metabolism. 2023-10-01
2 citations
Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized contro...
Vanita R Aroda, Juan Pablo Frias, Linong Ji, Elisabeth Niemoeller, My-Liên Nguyên-Pascal
Diabetes, Obesity & Metabolism. 2023-08-01

Press Mentions

Tirzepatide with Insulin Glargine Improves Type 2 DiabetesOctober 4th, 2023
Noninvasive Liver Screening Technology Enables Providers to Detect Liver Disease in Asymptomatic Patients, Identify at-Risk Patients for ReferralJune 9th, 2022
Echosens Underscores Impact of Obesity in Nonalcoholic Fatty Liver Disease & Metabolic Syndrome, Emphasizes Role of FibroScan to Monitor Liver Stiffness and Fat at Point-of-CareSeptember 15th, 2021
Join now to see all

Professional Memberships

Endocrine Society - ENDO
Member